ARTICLE | Clinical News
USL311: Phase I/II started
May 23, 2016 7:00 AM UTC
Upsher-Smith began an open-label, dose-escalation, international Phase I/II trial to evaluate once-weekly USL311 with or without lomustine every 6 weeks in 120 patients. The Phase I portion will enrol...